Spirituality & Health, Cancer & “the Old-Fashioned Way”
By Glenna Crooks | Monday, July 5th, 2010
By Glenna Crooks. Rittenhouse Square in Philly, a holiday weekend and great weather made for the perfect place for light reading this weekend. I got magazines with the intention of doing just that – and did. It was great to be outside on warm, breezy days.
However, my mood soured about half way into Spirituality&Health, reading an article about a possible new cancer therapy.
It describes the observations of Mamdooh Ghoneum, PhD: cancer cells are attracted to, ‘eat’ heat-killed baker’s yeast and then die. That’s good news. It happens in labs and in mice, who apparently suffer no side effects. That’s good news, too. Approval for testing in other animals is pending. I hope he gets it. We need progress in the healing of people with cancer.
Why the sour mood? Dr. Ghoneum is hero enough for making the observation and following through with studies. He’ll be all the more heroic if he continues and learns from whatever comes next.
The article does not stop with the ‘scientist vs disease’ heroic tale, however. It goes further to paint an unfortunate and ill-informed, biased contrast – between an altruistic pioneer using his personal savings and fund raising efforts to find a cure vs a greedy, patent-dependent industry hungry to return to shareholders the $800M – $2B quoted as the cost of developing a medicine. It asserts that industry would never develop a ‘natural’ product, saying: “Nowadays, a cancer cure that is all natural, non-toxic, simple to administer and inexpensive to produce has become an economic non-starter.”
Drug Development and Approval. Dr. Ghoneum is currently at the drug ‘research’ phase. This is the easy part. Get past animal research and the ‘development’ phase begins. Move into humans and the costs pile up fast – so do the failures. He’ll face institutional review boards, numerous negotiations with FDA over appropriate surrogate markers and end points, challenges of getting patients into clinical trials, careful management of clinical research sites and exquisite documentation at every stage. This is the phase that washes out all but 1-2 of every 10,000 drugs discovered.
Add to that, this is a yeast product – a biological – which means he’ll have to satisfy FDA that there is ‘batch to batch’ consistency in the product as he scales up for clinical studies and, if the product succeeds, eventual market use.
Since he intends to develop a treatment safe, effective and affordable enough for poor people around the world, he will also face regulatory requirements, and perhaps clinical trials, in those nations as well. (more…)














![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=906dfec8-985a-4570-903b-6124913939ca)
The following guest post by Malvise A. Scott, Senior Vice President, Partnership and Resource Development at National Association of Community Health Centers (and Former Community Health Center CEO), is part of Disruptive Women’s
The following guest post by Dr. Gunther L. Faber, CEO of The HealthStore Foundation®, is part of Disruptive Women’s 
